Women in menopause since at least 5 years, aged <85 years and with ≥2 vertebral fractures
Osteoporotic fractures after 1 and 3 years of treatment
2,458
First year of treatment: reduction of 46% (9–68%) with risedronate 2,5 mg and of 65% (38–81%) with risedronate 5 mg. After 3 years of treatment: reduction of 41% (18–57%)
After 3 years of treatment: reduction of 40% (6–61%)
Women in menopause since at least 5 years, aged 55–80 years, with 1–4 previous vertebral fractures and a T-score of −2.0 to −5.0 in at least one vertebral site
New morphometric vertebral fractures at 3 years of treatment
2,946
Reduction of 62% (41–75%) for daily dose and of 50% (26–66%) for intermittent dose
Women aged 45–54 years with T-score ≤ −3 and no previous fractures or T-score ≤ −2,5 and 1–4 previous fractures, and women ≥ 55 years with T-score ≤−2.5 and no previous fractures or T-score ≤ −2 and 1–4 previous fractures
New osteoporotic fractures or worsening of previous osteoporotic fractures after 18 months of treatment
Women aged 50–79 years with a BMD ≥ 3 than age-specific mean
Vertebral, hip, and other osteoporotic fractures
16,608
—
Reduction of 25% (17–32%)
Reduction of 33% (4–53%)
n.s.: not significant; BONE: oral iBandronate Osteoporosis vertebral fracture trial in North America and Europe; FIT: Fracture Intervention Trial; FPT: Fracture Prevention Trial; HIP: Hip Intervention Program; HORIZON: Health Outcomes and Reduced Incidence with Zoledronic Acid ONce yearly; MORE: Multiple Outcomes of Raloxifene Evaluation; SOTI: Spinal Osteoporosis Therapeutic Intervention; TROPOS: TReatment Of Peripheral OSteoporosis; TOP: Treatment of Osteoporosis with Parathyroid hormone; VERT: Vertebral Efficacy with Risedronate Therapy; WHI: Women's Health Initiative.